Medrx Co., Ltd

Teikoku Seiyaku Co., Ltd.

Nippon Shinyaku Company, Ltd.

Rohto Pharmaceutical Co., Ltd.

Beirsdorf Ag

Aspion Co., Ltd.

Anges Mg, Inc.

Hidetoshi Hamamoto

Katsunori Kobayashi

Masaki Ishibashi

Yasushi Miwa

Takahiro Tanimoto

Keiko Yamasaki

Katsuhiro Yamanaka

Naoya Akazawa

Hideakira Yokoyama

Takeru Fujii

Noboru Tatsumi

Kiyotsuna Toyohara

Sueko Matsumura

Takashi Oda

Koichi Masaoka

Taishi Tanaka

Takashi Shigeno

Tatsuhiro Ishida

Heiner Max

Sven Gohla

Manabu Ikarashi

Yasuko Abe

Thorsten Cassier

Kazuteru Kouno

Kazuya Adachi

Makiko Takemoto

Kazuteru Kohno

Akihiko Hirata

Takurou Kurita

Kanako Shiota

Mitsuru Endo

Shinya Maenosono

Keizo Ikari

Yasushi Suzuki

Yuji Makino

Hiroshi Akitomo

Miwa Yasushi

Makoto Sakaguchi

Akazawa Naoya

Kazuya Shinohara

Tatsuro Nakano

The present invention provides a novel siRNA specifically inhibiting the expression of IL-23 and a pharmaceutical composition comprising the siRNA specifically a double stranded RNA comprising a sense strand and an antisense strand wherein each strand has 19 to 30 nucleotides and comprises the base sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 or a complementary base sequence thereof and a pharmaceutical composition comprising the double stranded RNA.

Double stranded RNA specifically inhibiting expression of IL-23 and pharmaceutical composition comprising same

A non-aqueous patch preparation may include a drug solution in which a drug is dissolved in an organic solvent, a lipophilic mass base, and anhydrous silicic acid powders that are insoluble both in the organic solvent and in the lipophilic mass base. The organic solvent is selected from the group consisting of propylene glycol, 1,3-butanediol, polyethylene glycol, and propylene carbonate. The lipophilic mass base comprises an elastomer, a tackifier, and a softening agent wherein the elastomer is styrene-isoprene-styrene copolymer (SIS). The patch preparation has 2% to 10% by weight of the anhydrous silicic acid powders.

Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder

The present disclosure provides a patch preparation having features that prevent accidental use. In some embodiments, a patch preparation containing a plaster on a support, wherein the plaster comprises a solvent that is a combination of ethyl acetate and n-heptane. The patch preparation can lose its adhesion after the plaster is exposed to air and at least some of the solvent has evaporated, or if the patch is removed from the skin. This feature prevent the used patch from being applied to the skin again, and can prevent accidental use. A method of forming a patch preparation is also disclosed.

Patch preparations with accidental use prevention features

A microneedle patch applicator housing, being formed from a single sheet or film having a top surface and an undersurface, the housing including a flat peripheral base part and a raised part surround by the peripheral base part and bulging vertically, with respect to the peripheral base part, from the undersurface toward the top surface, an undersurface portion of the raised part forming a surface supporting a microneedle patch, the raised part including a plurality of concavely bent parts, and the concavely bent parts each having a concave bottom toward a direction away from a center portion of the raised part.

Microneedle patch applicator and housing for same

An object of the present invention is to provide a method for the treatment of a patient suffering from spasticity comprising administering to said patient a modified release dosage form comprising tizanidine or a pharmaceutically acceptable salt thereof. The present invention relates to a method of administering a transdermal patch preparation comprising tizanidine or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the transdermal patch preparation releases about 4 mg to about 36 mg of tizanidine or a pharmaceutically acceptable salt thereof for at least about 24 hours.

Tizanidine therapy system

A patch preparation which can produce the effect for preventing any problems due to the misuse of the patch preparation, includes a support and a plaster wherein the plaster includes a) an aliphatic compound with hydrophilic group which is in solid state at room temperature, b) a non-aqueous adhesive, and c) a solvent with a vapor pressure of 1 kPa or more at 20&#xb0; C.

Non-readherable adhesive patch

The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.

Percutaneous absorption composition

Provided are a method of applying a microneedle array, and a patch or an assistant tool used therefor. When skin is to be stretched and punctured with microneedles, the microneedle array can be prevented from detaching from the skin by providing adhesive layers, with the microneedle array therebetween, in a direction different from the direction in which the skin is stretched. Additionally, the application method can be appropriately implemented by producing a patch or an assistant tool having a rigid flat plate. As a result, the microneedle array can be punctured more accurately with less stress.

Microneedle patch

The purpose of the present application is to provide a microneedle patch applicator and a microneedle patch applicator housing, whereby perpendicular penetration properties of the needle into skin are enhanced. A microneedle patch applicator housing has a flat peripheral base part configured from a single sheet or film, and a protruding part which is surrounded by the peripheral base part and bulges perpendicularly upward toward a top surface from a bottom surface with respect to the peripheral base part. A bottom-surface portion of the protruding part constitutes part of a microneedle patch support surface. The protruding part is provided with a plurality of recessed fold parts, and the recessed fold parts have recess bottoms oriented in the direction away from a center part of the protruding part.

A device for inserting needles of a microneedle patch into a skin includes a housing. The housing includes a support portion for supporting a microneedle patch, a pressure-receiving portion to which the user applies a force to press the microneedle patch against the skin, and a plurality of leg portions each having at its one end a connecting portion connected to the pressure-receiving portion and having at its other end a tip portion coming into contact with the skin. The housing is designed to deform when a force is applied to the pressure-receiving portion, to cause a tension in a portion of the skin facing the support portion.

Microneedle applicator and microneedle patch application device

Package for containing a micro needle patch

A percutaneous absorption agent delivery device with: a solvent-impermeable cover film that has a first layer and a second layer, which are integrally continuous via a first fold and are superimposed, a non-seal region and a seal region are formed between the first layer and the second layer, the non-seal region disposed along the first fold, the seal region to surround the outer peripheral section of the non-seal region except for the section along the first fold, and an endless cut portion forming the non-seal region formed in the cover film; a percutaneous absorption agent carrying member is disposed in the non-seal region between the first layer and the second layer, and fixed to the cover film on the inner side of the cut portion; and an adhesive sheet that is detachably affixed to the outer surface of the cover film.

Percutaneous absorption agent delivery device and manufacturing method therefor

An object of the present invention is to provide a patch preparation having an excellent skin permeability of medicament using an acid additional salt of basic medicament. Provided is a patch preparation comprising a support and an adhesive layer on one surface of the support, wherein the adhesive layer contains a basic medicament, a fatty acid-based ionic liquid, and potassium salts and/or potassium ions. Said potassium salts and/or potassium ions are generated as a result of reaction of an acid addition salt of the basic medicament with a compound capable of generating potassium ion in the adhesive layer.

Patch preparation containing an acid scavenger

The present disclosure relates to a microneedle array having a pin frog shape which is coated with a drug composition comprising a drug and an additive and having Vickers hardness of about 3 or more is applied to a microneedle array. The microneedle array coated with the drug composition according to the present invention can be used in the field in which the drug is required to be administered with high quantitative performance even when the drug is contained at low content.

Microneedle array coated with drug composition

Growing community of inventors

Higashikagawa, Japan

Hidetoshi Hamamoto